Opportunity Assessment
Validate Indian physician and patient demand for your pharmaceutical product with primary research across therapeutic areas.
Learn more →
Our POV · 2026
India pharmaceutical market entry strategy
India's pharmaceutical market is the world's third-largest by volume and the fastest-growing major pharma market – with 1.4 billion patients, the world's most price-sensitive but high-volume branded generic market, government health insurance creating institutional procurement demand, and India's position as the pharmacy of the world creating export manufacturing opportunities. International pharmaceutical companies across branded generics, specialty pharmaceuticals, biologics, diagnostics, and API suppliers are all evaluating India as a priority market. GreyRadius helps pharma companies validate Indian market demand, navigate CDSCO regulatory requirements, identify distributors, and execute market entry.
Why now? India's Ayushman Bharat health insurance scheme covering 500 million people is creating the world's largest single government pharmaceutical procurement programme – companies empanelled with Ayushman Bharat hospitals gain access to a government-funded patient population at scale. The government's production-linked incentive for pharmaceuticals is creating API and formulation manufacturing investment opportunities simultaneously.
$130B
India pharmaceutical market by 2030
Growing at 12% annually as health insurance expansion, chronic disease burden, and specialty pharma adoption drive demand.
30+
Primary interviews per India pharma mandate
Indian physicians, hospital pharmacists, and pharmaceutical distributors – every engagement grounded in direct primary research.
10 weeks
India pharmaceutical market entry strategy
AI-augmented CDSCO regulatory mapping and physician demand research delivers India pharmaceutical market entry strategies efficiently.
Market Intelligence
What the data says.
India's pharmaceutical market is projected to reach $130B by 2030 – growing at 12% annually as health insurance expansion, chronic disease burden, and specialty pharma adoption all drive demand.
India is the world's largest generic medicine producer – supplying 20% of global generic medicines and creating a sophisticated pharmaceutical distribution and regulatory infrastructure that international companies can leverage.
Specialty pharmaceuticals are growing at 20% annually – oncology, rare diseases, and biologic medicines are all seeing rapid adoption among India's growing specialist physician community.
Biosimilars are India's fastest-growing pharma segment – Indian biotech companies producing biosimilars for domestic and export markets are creating manufacturing partnership and supply chain opportunities.
Market Reality
What makes this market hard.
- CDSCO drug registration is complex – new drug applications, bioequivalence studies, and clinical trial requirements all apply to branded pharmaceutical products entering India.
- Indian pharmaceutical pricing regulation is strict – NPPA drug price controls apply to essential medicines and affect commercial viability of government-empanelled products.
- Distribution requires a national pharma distributor – reaching India's 900,000+ chemists and hospital pharmacies requires a national pharmaceutical distributor with established coverage.
- Competition from Indian generic manufacturers – Cipla, Sun Pharma, and Dr. Reddy's – with cost advantages is intense across all generic and branded generic categories.
Our Work
What we solve for clients.
If you recognise your situation below, we can help.
India pharma market demand validation
You need to validate Indian physician, patient, and institutional demand for your pharmaceutical product including pricing and channel requirements.
CDSCO regulatory pathway
You need to understand CDSCO new drug application, clinical trial, and bioequivalence requirements for your pharmaceutical product.
India pharma distribution partner identification
You need a national pharmaceutical distributor, hospital pharmacy channel partner, and e-pharmacy platform for your product.
India pharma GTM strategy
You need a go-to-market plan covering physician detailing, hospital formulary listing, and chemist distribution.
Raising capital for India pharma investment
You need a pitch book grounded in India pharmaceutical market data and CDSCO regulatory timeline.
Ayushman Bharat empanelment strategy
You need a strategy for hospital empanelment and government insurance procurement access.
Our Services
How we engage.
Every engagement is grounded in primary research and delivers a measurable outcome.
Feasibility & TEV
Full financial feasibility for India pharma investment covering CDSCO compliance cost and distribution economics.
Learn more →Market Entry Execution
End-to-end India pharma market entry including CDSCO pathway, distributor identification, and first-prescription milestone.
Learn more →GTM Execution-as-a-Service
Embedded India pharma GTM team covering physician detailing and hospital pharmacy outreach.
Learn more →Pitchbook & Fundraising
Investor-ready pitch books for India pharma investment with health insurance expansion narrative.
Learn more →AI Consulting
AI use-case identification – from Hindi language patient adherence support to physician detailing optimisation for Indian prescribing patterns.
Learn more →Why GreyRadius.
Primary research-led
80% of our insight comes from first-party interviews with buyers, competitors, and regulators – not secondary data that everyone else has.
Expert-led, AI-enabled delivery
Our AI layer compresses research timelines by 60% and surfaces pattern-matching from 200+ prior mandates – so you get faster, deeper answers.
Outcomes, not reports
We measure success by first contracts signed, capital raised, and markets entered – not deliverables produced. Every mandate has a milestone.
200+
Projects delivered
100+
SaaS & tech clients
80%
Primary research-led
4
Countries / offices
Case Studies
Mandates we've run.
Pharma & Life Sciences · Market Entry
Sector-specific case studies available on request.
Primary researchFirst contract
View all case studies →FAQ
Common questions.
Does GreyRadius work with branded generic companies or also with specialty pharma, biologics, and API suppliers entering India?+
All pharmaceutical categories.
How long does an India pharma market entry engagement take?+
Typically 10–14 weeks given CDSCO regulatory complexity and distribution network mapping.
Can GreyRadius identify national pharmaceutical distributors for international pharma companies in India?+
Yes – national distributor identification and initial commercial introductions are core to our India pharma market entry service.
How does Ayushman Bharat affect pharmaceutical market entry strategy?+
AB creates a large government-funded patient population at hospital empanelled facilities – we assess AB empanelment strategy in every India pharma engagement.
Stay informed
Market intelligence for Pharma & Life Sciences leaders.
GreyRadius research notes, market entry signals, and sector briefs – delivered weekly. No fluff.
Not sure which engagement fits? Take our free 2-minute diagnostic →
Related market entry guides
Ready to enter this market?
Primary research. AI-enabled analysis, expert-reviewed. Outcomes-based delivery – across Gulf, Southeast Asia, South Asia.